Zydus Ties Up With Synthon for MS Drug in US
ECONOMY & POLICY

Zydus Ties Up With Synthon for MS Drug in US

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).
The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.
As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.
“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.
The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.
This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Related Stories

Gold Stories

Next Story
Infrastructure Urban

KONE Opens India's First Digital Experience Centre in Pune

KONE, a global elevator and escalator manufacturer, has inaugurated its first Digital Experience Centre (DEC) in India, located in Pune. The facility aims to showcase how artificial intelligence (AI), connectivity and data-driven technologies can enhance customer experiences and improve building operations.The centre was inaugurated by Jussi Herlin, Executive Vice Chair, KONE Corporation; Philippe Delorme, President and CEO, KONE; and Nandan Nilekani, Co-founder and Chairman of the Board, Infosys.Designed as an interactive customer environment, the facility demonstrates digital solutions cover..

Next Story
Infrastructure Urban

CII GreenCo Launches Circularity Guidelines for Indian Industry

The Confederation of Indian Industry (CII) GreenCo Council has launched the CII GreenCo Circularity Guidelines – Pilot Version at the 17th CII GreenCo Waste & Resource Management Summit 2026 in Chennai. The initiative aims to strengthen resource efficiency, waste reduction and circular economy practices across Indian manufacturing and process industries.The guidelines introduce a structured framework with circularity indices covering raw materials, consumables, packaging and other resource inputs. These indicators will help industries assess existing practices, identify opportunities to ..

Next Story
Infrastructure Energy

Global Electronics Association Launches IPC-1783-CO2E Standard

The Global Electronics Association has introduced IPC-1783-CO2E, a new international standard aimed at improving consistency, transparency and comparability in product carbon footprint reporting across the electronics manufacturing industry.The standard, titled International Standard for Data Collection and Reporting of CO2 Equivalent (CO2e) Emissions for the Electronics Manufacturing Supply Chain, provides industry-specific guidance for collecting, estimating and reporting carbon emissions data.With increasing regulatory requirements and customer expectations, electronics manufacturers face c..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code